N/A N=12 rTMS and Botulinum Toxin in Benign Essential Blepharospasm
Benign Essential Blepharospasm
Primary: Change in JRS Severity Score — -1.8; -0.1 Change in score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=65 Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
Blepharospasm
Primary: Change From Baseline to Week 4 in Blepharospasm Disability Index — -2.8; -1.3 Points on Scale
Phase 3 N=61 Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid
Bilateral Blepharospasm (BEB)
Primary: Double-blind MP: Change From Baseline in JRS Severity Subscore at Day 43 (Visit 4) — -0.6; -1.0; -1.8 score on a scale — p==0.0004
Phase 2 N=24 A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm
Focal Dystonia
Primary: Time Until Jankovic Blepharospasm Rating Scale (JBRS) Reverts Back to Baseline — 3.71; 3.03 month
Phase 3 N=109 IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
Blepharospasm
Primary: Jankovic Rating Scale (JRS) Change From Baseline in the JRS Severity Subscore at Week 6 After Injection (Assessed by a Blinded Independent Rater) — -0.8; 0.2 Points on a…
Phase 2 N=33 LEV102 Topical Gel in Acquired Blepharoptosis
Acquired Blepharoptosis
Primary: Percentage of Subjects With Treatment-Emergent Adverse Events [Safety and Tolerability]) — 0; 0; 0 Participants
N/A N=16 Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis
Blepharoptosis · Ptosis, Eyelid · Myasthenia Gravis
Primary: Interpalpebral Fissure (IPF) During Spontaneous Blink — 2.4; 4.1; 1.1 millimeters — p=<0.001
Phase 2 N=46 Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis
Blepharoptosis
Primary: Humphrey Visual Field — 9.8; 12.1; 11.1; 16.1 Points seen
Phase 3 N=234 Study of Safety of RVL-1201 in Treatment of Blepharoptosis
Blepharoptosis
Primary: Mean Change From Baseline in Intraocular Pressure (IOP) at Day 84 — -0.6; -0.2; -0.6; -0.2 mmHg
Phase 3 N=164 Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
Blepharoptosis
Primary: Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group — 6.3; 2.1; 7.7; 2.4 Points seen — p=<0.0001
Phase 3 N=140 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
Acquired Blepharoptosis
Primary: Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group — 5.2; 1.5; 6.4; 2.2 Points seen — p=<0.0001
Phase 2 N=121 A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
Allergic Conjunctivitis
Primary: Ocular Itching — 1.908; 1.925; 1.177; 2.758 units on a scale — p=0.0002
Phase 4 N=40 The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer
Allergic Conjunctivitis
Primary: Tear Osmolarity — 303; 303 mOsM/L
Phase 3 N=228 A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.
Allergic Conjunctivitis
Primary: Ocular Itching — 1.609; 1.886; 2.219; 1.750 units on a scale — p=< 0.0001
Phase 3 N=130 Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching — 0.4; 1.9; 0.4; 0.5 Units on a scale
N/A N=19 Clinical Trial to Improve the Magnetic Levator Prosthesis
Blepharoptosis · Ptosis, Eyelid · Myasthenia Gravis
Primary: Change in Interpalpebral Fissure During Eye Opening — 4.5; 6.9; 6.2; 6.3 millimeters — p=>=0.46
N/A N=197 Bilateral Lateral Rectus Recession Versus Unilateral Recess-Resect for Intermittent Exotropia
Exotropia
Primary: Number of Participants With Suboptimal Surgical Outcome as Assessed by Motor Alignment and Stereoacuity at Near by 3 Years — 43; 33 Participants — p=0.24
Phase 2 N=36 Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis
Blepharitis
Primary: COHORT 1 and 2 COMBINED: Mean Change From Baseline to Day 14 in the Composite (Sum) Score of Signs & Symptoms of Blepharitis — -2.0; -1.2 units on a scale — p=0.0471
Phase 4 N=30 Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis
Blepharitis
Primary: Improvement in Signs and Symptoms of Blepharitis — 15; 15 participants
N/A N=22 Transcranial Magnetic Stimulation for BECTS
Benign Epilepsy With Centrotemporal Spikes · Language Problems · Learning Disorders
Primary: Interictal Epileptiform Discharge (IED) Frequency — 0; 0; 0; 0 IEDs per 5 minutes — p=0.04
N/A N=11 Magnetic Correction of Eye Lid Paralysis
Blepharoptosis · Lagophthalmos · Facial Paralysis
Primary: Rating Scale of Skin Integrity — 0.3 units on a scale
Early Phase 1 N=15 Topical Bimatoprost for Chemical Blepharoplasty
Dermatochalasis
Primary: Graded Change in Dermatochalasis — .2679 units on a scale
Phase 3 N=107 Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Ocular Itching — 0.5; 1.9; 0.6; 0.8 Units on a scale
Phase 2 N=95 Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction
Meibomian Gland Dysfunction
Primary: IOP Related to Safety — 15.906; 16.452; 16.469 mmHg
Phase 3 N=357 Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis
Conjunctivitis · Keratitis · Blepharitis
Primary: Signs and Symptoms Composite Score - Change From Baseline to Day 15 - PP Population — -11.63; -12.41 Scores on a scale
N/A N=40 Symmetric vs Asymmetric BLR Recession in Management of Basic IXT With Ocular Dominance
Intermittent Exotropia
Primary: Ocular Alignment at Distant Fixation — 5.8; 1.1 prism diopter
Phase 4 N=23 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Change From Baseline in Ocular Itching at 14 Days — 2.17; 1.82 units on a scale
Phase 2 N=245 Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients
Allergic Conjunctivitis
Primary: Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) - Mean Change in Total Score — -1.18; -1.17 score on a scale
Phase 3 N=355 Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)
Glabellar Frown Lines
Primary: Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline, Based on Both the…
Phase 4 N=35 VISmodegib for ORbital and Periocular Basal Cell Carcinoma
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants